skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 1 - 20 of 3,925  for All Library Resources

Results 1 2 3 4 5 next page
Show only
Result Number Material Type Add to My Shelf Action Record Details and Options
1
PCSK9: A Key Modulator of Cardiovascular Health
Material Type:
Article
Add to My Research

PCSK9: A Key Modulator of Cardiovascular Health

Circulation research, 2014-03, Vol.114 (6), p.1022-1036 [Peer Reviewed Journal]

2014 American Heart Association, Inc. ;ISSN: 0009-7330 ;EISSN: 1524-4571 ;DOI: 10.1161/CIRCRESAHA.114.301621 ;PMID: 24625727

Full text available

2
Targeting the Proprotein Convertase Subtilisin/Kexin Type 9 for the Treatment of Dyslipidemia and Atherosclerosis
Material Type:
Article
Add to My Research

Targeting the Proprotein Convertase Subtilisin/Kexin Type 9 for the Treatment of Dyslipidemia and Atherosclerosis

Journal of the American College of Cardiology, 2013-10, Vol.62 (16), p.1401-1408 [Peer Reviewed Journal]

American College of Cardiology Foundation ;2013 American College of Cardiology Foundation ;2015 INIST-CNRS ;Copyright © 2013 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. ;Copyright Elsevier Limited Oct 15, 2013 ;ISSN: 0735-1097 ;EISSN: 1558-3597 ;DOI: 10.1016/j.jacc.2013.07.056 ;PMID: 23973703 ;CODEN: JACCDI

Full text available

3
Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition: A New Therapeutic Mechanism for Reducing Cardiovascular Disease Risk
Material Type:
Article
Add to My Research

Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition: A New Therapeutic Mechanism for Reducing Cardiovascular Disease Risk

Circulation (New York, N.Y.), 2015-10, Vol.132 (17), p.1648-1666 [Peer Reviewed Journal]

2015 by the American College of Cardiology Foundation and the American Heart Association, Inc. ;2015 American Heart Association, Inc. ;ISSN: 0009-7322 ;EISSN: 1524-4539 ;DOI: 10.1161/CIRCULATIONAHA.115.016080 ;PMID: 26503748

Full text available

4
Revisiting Proinsulin Processing: Evidence That Human β-Cells Process Proinsulin With Prohormone Convertase (PC) 1/3 but Not PC2
Material Type:
Article
Add to My Research

Revisiting Proinsulin Processing: Evidence That Human β-Cells Process Proinsulin With Prohormone Convertase (PC) 1/3 but Not PC2

Diabetes (New York, N.Y.), 2020-07, Vol.69 (7), p.1451-1462 [Peer Reviewed Journal]

2020 by the American Diabetes Association. ;Copyright American Diabetes Association Jul 1, 2020 ;ISSN: 0012-1797 ;EISSN: 1939-327X ;DOI: 10.2337/db19-0276 ;PMID: 32291281

Full text available

5
The PCSK9 decade
Material Type:
Article
Add to My Research

The PCSK9 decade

Journal of lipid research, 2012-12, Vol.53 (12), p.2515-2524 [Peer Reviewed Journal]

2012 © 2012 ASBMB. Currently published by Elsevier Inc; originally published by American Society for Biochemistry and Molecular Biology. ;ISSN: 0022-2275 ;EISSN: 1539-7262 ;DOI: 10.1194/jlr.R026658 ;PMID: 22811413

Full text available

6
Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol
Material Type:
Article
Add to My Research

Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol

The New England journal of medicine, 2012-03, Vol.366 (12), p.1108-1118 [Peer Reviewed Journal]

Copyright © 2012 Massachusetts Medical Society. All rights reserved. ;2015 INIST-CNRS ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1105803 ;PMID: 22435370 ;CODEN: NEJMAG

Full text available

7
A Highly Durable RNAi Therapeutic Inhibitor of PCSK9
Material Type:
Article
Add to My Research

A Highly Durable RNAi Therapeutic Inhibitor of PCSK9

The New England journal of medicine, 2017-01, Vol.376 (1), p.41-51 [Peer Reviewed Journal]

Copyright © 2016 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1609243 ;PMID: 27959715

Full text available

8
Mouse Models of Human Proprotein Convertase Insufficiency
Material Type:
Article
Add to My Research

Mouse Models of Human Proprotein Convertase Insufficiency

Endocrine reviews, 2021-06, Vol.42 (3), p.259-294 [Peer Reviewed Journal]

The Author(s) 2020. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com 2020 ;The Author(s) 2020. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. ;COPYRIGHT 2021 Oxford University Press ;The Author(s) 2020. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com ;ISSN: 0163-769X ;EISSN: 1945-7189 ;DOI: 10.1210/endrev/bnaa033 ;PMID: 33382413

Full text available

9
Suppressor of Cytokine Signaling-3 (SOCS-3) Induces Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Expression in Hepatic HepG2 Cell Line
Material Type:
Article
Add to My Research

Suppressor of Cytokine Signaling-3 (SOCS-3) Induces Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Expression in Hepatic HepG2 Cell Line

The Journal of biological chemistry, 2016-02, Vol.291 (7), p.3508-3519 [Peer Reviewed Journal]

2016 © 2016 ASBMB. Currently published by Elsevier Inc; originally published by American Society for Biochemistry and Molecular Biology. ;2016 by The American Society for Biochemistry and Molecular Biology, Inc. ;2016 by The American Society for Biochemistry and Molecular Biology, Inc. 2016 The American Society for Biochemistry and Molecular Biology, Inc. ;ISSN: 0021-9258 ;EISSN: 1083-351X ;DOI: 10.1074/jbc.M115.664706 ;PMID: 26668321

Full text available

10
Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab
Material Type:
Article
Add to My Research

Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab

The New England journal of medicine, 2017-04, Vol.376 (16), p.1517-1526 [Peer Reviewed Journal]

Copyright © 2017 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;ISSN: 1533-4406 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1614062 ;PMID: 28304227

Full text available

11
Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial
Material Type:
Article
Add to My Research

Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial

The Lancet (British edition), 2014-01, Vol.383 (9911), p.60-68 [Peer Reviewed Journal]

Elsevier Ltd ;2014 Elsevier Ltd ;2015 INIST-CNRS ;Copyright © 2014 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Jan 4, 2014 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(13)61914-5 ;PMID: 24094767 ;CODEN: LANCAO

Full text available

12
PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future
Material Type:
Article
Add to My Research

PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future

European heart journal, 2015-09, Vol.36 (36), p.2415-2424 [Peer Reviewed Journal]

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2015. For permissions please email: journals.permissions@oup.com. ;ISSN: 0195-668X ;EISSN: 1522-9645 ;DOI: 10.1093/eurheartj/ehv174 ;PMID: 25971287

Full text available

13
A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
Material Type:
Article
Add to My Research

A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia

The New England journal of medicine, 2014-05, Vol.370 (19), p.1809-1819 [Peer Reviewed Journal]

Copyright © 2014 Massachusetts Medical Society. All rights reserved. ;2015 INIST-CNRS ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1316222 ;PMID: 24678979 ;CODEN: NEJMAG

Full text available

14
PCSK9 deficiency reduces atherosclerosis, apolipoprotein B secretion, and endothelial dysfunction
Material Type:
Article
Add to My Research

PCSK9 deficiency reduces atherosclerosis, apolipoprotein B secretion, and endothelial dysfunction

Journal of lipid research, 2018-02, Vol.59 (2), p.207-223 [Peer Reviewed Journal]

2018 Copyright © 2018 by the American Society for Biochemistry and Molecular Biology, Inc. ;Copyright © 2018 by the American Society for Biochemistry and Molecular Biology, Inc. ;Copyright Journal of Lipid Research Feb 2018 ;Copyright © 2018 by the American Society for Biochemistry and Molecular Biology, Inc. 2018 ;ISSN: 0022-2275 ;EISSN: 1539-7262 ;DOI: 10.1194/jlr.M078360 ;PMID: 29180444

Full text available

15
Inhibition of PCSK9 Transcription by Berberine Involves Down-regulation of Hepatic HNF1α Protein Expression through the Ubiquitin-Proteasome Degradation Pathway
Material Type:
Article
Add to My Research

Inhibition of PCSK9 Transcription by Berberine Involves Down-regulation of Hepatic HNF1α Protein Expression through the Ubiquitin-Proteasome Degradation Pathway

The Journal of biological chemistry, 2015-02, Vol.290 (7), p.4047-4058 [Peer Reviewed Journal]

2015 © 2015 ASBMB. Currently published by Elsevier Inc; originally published by American Society for Biochemistry and Molecular Biology. ;2015 by The American Society for Biochemistry and Molecular Biology, Inc. ;2015 by The American Society for Biochemistry and Molecular Biology, Inc. 2015 ;ISSN: 0021-9258 ;EISSN: 1083-351X ;DOI: 10.1074/jbc.M114.597229 ;PMID: 25540198

Full text available

16
Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol
Material Type:
Article
Add to My Research

Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol

The New England journal of medicine, 2017-04, Vol.376 (15), p.1430-1440 [Peer Reviewed Journal]

Copyright © 2017 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1615758 ;PMID: 28306389

Full text available

17
Low-Density Lipoprotein Cholesterol―Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia: The Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) Randomized Trial
Material Type:
Article
Add to My Research

Low-Density Lipoprotein Cholesterol―Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia: The Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) Randomized Trial

Circulation (New York, N.Y.), 2012-11, Vol.126 (20), p.2408-2417 [Peer Reviewed Journal]

2015 INIST-CNRS ;ISSN: 0009-7322 ;EISSN: 1524-4539 ;DOI: 10.1161/CIRCULATIONAHA.112.144055 ;PMID: 23129602 ;CODEN: CIRCAZ

Full text available

18
Clinical Genetic Testing for Familial Hypercholesterolemia: JACC Scientific Expert Panel
Material Type:
Article
Add to My Research

Clinical Genetic Testing for Familial Hypercholesterolemia: JACC Scientific Expert Panel

Journal of the American College of Cardiology, 2018-08, Vol.72 (6), p.662-680 [Peer Reviewed Journal]

Copyright © 2018 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. ;Copyright Elsevier Limited Aug 7, 2018 ;ISSN: 0735-1097 ;EISSN: 1558-3597 ;DOI: 10.1016/j.jacc.2018.05.044 ;PMID: 30071997

Full text available

19
PCSK9 Induces CD36 Degradation and Affects Long-Chain Fatty Acid Uptake and Triglyceride Metabolism in Adipocytes and in Mouse Liver
Material Type:
Article
Add to My Research

PCSK9 Induces CD36 Degradation and Affects Long-Chain Fatty Acid Uptake and Triglyceride Metabolism in Adipocytes and in Mouse Liver

Arteriosclerosis, thrombosis, and vascular biology, 2015-12, Vol.35 (12), p.2517-2525 [Peer Reviewed Journal]

2015 American Heart Association, Inc. ;Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 1079-5642 ;EISSN: 1524-4636 ;DOI: 10.1161/ATVBAHA.115.306032 ;PMID: 26494228

Full text available

20
In vivo genome editing using Staphylococcus aureus Cas9
Material Type:
Article
Add to My Research

In vivo genome editing using Staphylococcus aureus Cas9

Nature (London), 2015-04, Vol.520 (7546), p.186-191 [Peer Reviewed Journal]

COPYRIGHT 2015 Nature Publishing Group ;COPYRIGHT 2015 Nature Publishing Group ;Copyright Nature Publishing Group Apr 9, 2015 ;ISSN: 0028-0836 ;EISSN: 1476-4687 ;DOI: 10.1038/nature14299 ;PMID: 25830891 ;CODEN: NATUAS

Full text available

Results 1 - 20 of 3,925  for All Library Resources

Results 1 2 3 4 5 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Show only

  1. Peer-reviewed Journals (3,720)

Refine My Results

Creation Date 

From To
  1. Before 1991  (28)
  2. 1991 To 1998  (371)
  3. 1999 To 2006  (505)
  4. 2007 To 2015  (924)
  5. After 2015  (2,096)
  6. More options open sub menu

Language 

  1. English  (3,863)
  2. Japanese  (752)
  3. German  (26)
  4. Spanish  (13)
  5. French  (12)
  6. Portuguese  (11)
  7. Russian  (10)
  8. Norwegian  (8)
  9. Chinese  (5)
  10. Swedish  (3)
  11. Polish  (2)
  12. Korean  (2)
  13. Turkish  (1)
  14. Croatian  (1)
  15. More options open sub menu

Searching Remote Databases, Please Wait